3161results about How to "Avoid side effects" patented technology

Methods and apparatus are disclosed for applying acoustic energy to the skin. Acoustic waveguides with elements of varying thickness or shape are disclosed which deliver energy to more than one depth below a surface of the skin substantially simultaneously. The invention is especially useful with devices that focus ultrasound energy by condensing a propagating wavefront. The invention compensates for the mismatch in acoustic properties of the device's waveguide and the biological tissue that typically cause portions of the collapsing wavefront to lag behind other portions and, thereby, limit the focusing capabilities of acoustic treatment devices.

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

Methods and apparatus are disclosed for applying acoustic energy to the skin whereby the wavefront can be controlled to confine the focused energy to a desired subsurface region. Acoustic waveguides are disclosed which compensate for distortions that otherwise occur when a focused acoustic beam crosses a boundary, such as the transition from a treatment device to a target region of skin. The invention is especially useful with devices that focus ultrasound energy by condensing a propagating wavefront. The invention compensates for the mismatch in acoustic properties of the device's waveguide and the biological tissue that typically cause portions of the collapsing wavefront to lag behind other portions and, thereby, limit the focusing capabilities of acoustic treatment devices.

Methods and apparatus are disclosed for dispensing fluid in an apparatus for applying acoustic energy to the skin. Acoustic waveguides are disclosed which compensate for distortions that otherwise occur when a focused acoustic beam crosses a boundary, such as the transition from a treatment device to a target region of skin. The invention is especially useful with devices that focus ultrasound energy by condensing a propagating wavefront. The invention compensates for the mismatch in acoustic properties of the device's waveguide and the biological tissue that typically cause portions of the collapsing wavefront to lag behind other portions and, thereby, limit the focusing capabilities of acoustic treatment devices.

An apparatus for creating therapeutic charge transfer in tissue includes a coil. The coil generates a changing magnetic field to induct an electric field in the tissue exceeding 10 mV / cm when the coil is 5 cm from the tissue. Preferably, the magnetic field has a growth phase and a decay phase and a duration of the growth phase is at least ten times a duration of the decay phase. The apparatus can include a control circuit to control a current fed to the coil. The control circuit includes two subcircuits and a switch for switching between a first of the subcircuits and a second of the subcircuits; preferably, a λ of the second subcircuit is at least ten times a λ of the first subcircuit. To generate the therapeutic effect, the coil should have a duty cycle of at least ten percent.

Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.

Method and system to provide therapy for obesity, gastric motility, or to induce weight loss comprises ablating the gastric tissue around the “pacemaker” region of the stomach, and electrically pacing the stomach with a pulse generator / stimulator to control the electrical activity of the gastric muscle. The ablation to the gastric tissue may be from the epigastric side, or may be from inside the stomach. The ablation may be performed utilizing any one of: radiofrequency catheter ablation; radiofrequency catheter ablation using an irrigated tip catheter; microwave ablation; cryoablation; high intensity focused ultrasound (HIFU) ablation; and laser ablation. The ablation of the “pacemaker” region of the stomach may be partial or complete. A gastric pulse generator / stimulator is implanted to provide electrical pulses to the stomach. The function of the gastric stimulator after complete ablation of the pacemaker region, is to provide a basic electrical rhythm (BER) to regulate and control electrical activity of the stomach. Alternatively, if partial ablation is performed the function of the gastric pulse generator / stimulator is to enhance the residual basic electrical rhythm (BER), or to interfere with the residual basic electrical rhythm (BER).

Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NFκB family of transcription factors.

The invention relates to a PMSM servo system control method based on fuzzy and active disturbance rejection control. A position signal is given by a differential tracker to arrange a transition process so that the contradiction between rapidness and overshoot of a system is solved, and uncertainty, friction torques and external disturbance due to modeling errors of the system are observed via an expansion state observer; according to the error between the differentials generated by the differential tracker and state variation generated by the expansion state observer, a fuzzy inference rule is obtained with application of experimental experience of technical staff, so that a fuzzy rule control table of an error proportion coefficient, a differential coefficient and an integration coefficient is established; accurate control amount is obtained after de-fuzzification, so that parameter self-adaptive adjustment of a nonlinear error feedback control law is realized; and compensation amounts of the nonlinear error feedback control law and the expansion state observer to the total disturbance forms the control amount, thereby realizing optimal control for an controlled object. The method of the invention improves both tracking precision and disturbance rejection capability of the system.

The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.

It is intended to provide highly stable variants of human antibody IgG2 and IgG3 subclasses. The present invention provides an IgG heavy chain comprising the constant region of a human IgG2 heavy chain having at least a substitution of Y for F at the 300th position, L for V at the 309th position, or A for T at the 339th position designated by the EU index of Kabat et al. and an IgG heavy chain comprising the constant region of a human IgG3 heavy chain having at least a substitution of K for N at the 392nd position or V for M at the 397th position designated by the EU index of Kabat et al. The present invention also provides monoclonal antibodies comprising these heavy chains.

The invention discloses an anti-microbial healing-promoting hydrogel dressing and a preparation method therefor. The main ingredients of the dressing are water-soluble high-molecular polymers, functional polymers with pseudoplastic, anti-microbial agents and water. The above ingredients are dissolved into a whole after a series of technologies. The solution is poured into a mold, and the hydrogel dressing is obtained after curing and irradiation disinfection. The results of wound healing experiments and in vitro anti-microbial experiments show that the hydrogel dressing can promote wound healing effectively, and has good bacteriostatic activity to multiple bacteria (the sterilizing rate is above 70%). The anti-microbial healing-promoting hydrogel dressing is better than existing hydrogel dressings obviously, and has advantages of substantial anti-microbial curative effects, transparency, high water content, simple preparation method, pure product, nontoxicity, innocuousness, no stimulation, good biocompatibility and the like. The hydrogel dressing is suitable for large-area promotion and application.

A method of treating anti-neutrophil cytoplasmic antibodies-associated vasculitis (ANCA-associated vasculitis) in a patient eligible for treatment is provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the patient in a dose of about 400 mg to 1.3 grams at a frequency of one to three doses within a period of about one month. Another method of treating ANCA-associated vasculitis in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens. Further provided are articles of manufacture useful for such methods.

The invention provides a local concentration management system (LCMS) for delivery of highly concentrated therapeutic agent formulations. The LCMS comprises a device comprising an elongate body defining a lumen between its proximal and distal ends, and a diffuser element, a dilutor element, or both. The diffuser element, which is selectively permeable to the agent, is operatively associated with the elongate body so that agent flows through the elongate body, and into and through the diffuser element to exit the system. The dilutor element can be operatively associated with the system to be in fluid communication with the elongate body lumen, a diffusion space defined by a diffuser element inner wall, or both. The dilutor element is selectively water permeable, but substantially impermeable to agent, to provide for dilution of the agent during transit through the system. The LCMS system is designed to disperse and / or dilute the drug delivery stream.

The present invention relates to methods and compositions for treating disorders of the central and / or peripheral nervous system by administering agents that are effective in reducing the effective amount, inactivating, and / or inhibiting the activity of a Na+—K+—2CT (NKCC) cotransporter. In certain embodiments, the Na+—K+—2Cl− co-transporter is NKCC1.

The invention discloses a method for controlling a PMSM (permanent magnet synchronous motor) servo system based on friction and disturbance compensation. In the method, a feedforward compensation method based on a friction model is combined with an auto disturbance rejection technology and the feedforward compensation method is complementary with the auto disturbance rejection technology mutually. In the method, a Stribeck friction model is utilized to carry out modeling on system frictions, a GA (genetic algorithm) is adopted to carry out offline identification on parameters, and an estimated value generated by an identification model carries out feedforward compensation; a state observer in the auto disturbance rejection technology observes and compensates overcompensation or undercompensation of the frictions as well as nondeterminacy and external disturbance caused by modeling errors in the system; and finally a differential tracker and a nonlinear control law are used to arrange a transient process for fixed position signals, thus solving the conflict between rapidity and overstrike and ensuring stability of the system and finite time convergence. By using the combined control, the compensation capacity of the system for the frictional nonlinearity can be improved effectively, the low-speed performance of the system is improved, and the tracking accuracy and the anti-disturbance capacity of the system are enhanced.

The invention provides a composition for promoting regeneration of tissue which has degenerated in a subject as a result of a disease or disorder and a method of using the composition is provided. The composition comprises a biodegradable acellular matrix, and passaged autologous fibroblasts substantially free of immunogenic proteins, e.g., culture medium serum-derived proteins, integrated within the matrix. Also provided is an injectable composition comprising an acellular filler material (e.g., any type of collagen) and passaged autologous fibroblasts substantially free of immunogenic proteins, e.g., culture medium serum-derived proteins, for correcting defects in skin, such as wrinkles or scars, and for augmenting tissue in the subject, particularly facial tissue.

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

The present invention provides pharmaceutical formulations of cytidine analogs and derivatives, such as 5-azacytidine, 5-aza-2′-deoxy-2′,2′-difluorocytidine, 5-aza-2′-deoxy-2′-fluorocytidine, 2′-deoxy-2′,2′-difluorocytidine, and cytosine 1-β-D-arabinofuranoside, as well as methods of manufacturing the formulations. In particular, the cytidine analog or derivative is formulated with a cyclodextrin compound to stabilize and / or enhance solubility of the drug. Kits and methods for using the pharmaceutical formulations are also provided, including methods of administering the cytidine analog or derivative to treat conditions or diseases, such as cancer and hematological disorders.

The invention discloses a method of administering a pharmaceutical combination comprising an NSAID and a slow release tramadol to a mammal in need of thereof. This invention further discloses an analgesic combination comprising an NSAID and a slow release tramadol for treating pain and pain related conditions.

Image compression, decompression and motion detection methods are described. Two temporally adjacent frame images, a previous time frame and a current time frame, are compressed in round-off and averaging techniques. Next, according to the compressed data of two corresponding pixels of the two frame images, whether or not the pixel of the current time frame image is of a motion picture is detected. If the pixel is of a motion picture, the compressed pixel data of the previous time frame image is decompressed, and an overdrive process is performed on the decompressed pixel data and the original pixel data of the current time frame image to produce an overdrive output. If the pixel is not of a motion picture, an overdrive process is not performed.

The invention discloses a novel composite conductive agent, a lithium ion positive pole piece and a lithium ion negative pole piece made of the composite conductive agent, and a lithium ion battery containing the positive pole piece and the negative pole piece. By leading the novel composite conductive agent, the developed pole piece of which the surface has an effective conductive network can be prepared by adding a small amount of conductive agent, so that the prepared lithium ion has excellent rate discharging, low-temperature discharging, high-temperature storage and cyclic properties. The composite conductive agent comprises single-wall or fewer-wall carbon nanotubes and graphene nanosheets, wherein the specific surface area of each single-wall or fewer-wall carbon nanotube is 200 to 1500m<2> / g, the tube diameter is 1 to 10nm, and the tube length is greater than 5mu m; the diameter of each graphene nanosheet is 0.2 to 2mu m, the specific surface area is smaller than 1800m<2> / g, and the thickness is smaller than 2nm.

The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.

Methods are provided for, inter alia, treating and / or preventing symptoms associated with multiple sclerosis and MS relapse.

A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a calcium channel blocker is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred calcium channel blockers are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9alpha,11alpha-substituted epoxy moiety. A preferred combination therapy includes the calcium channel blocker verapamil HCl (Benzenacetonitrile, (±)-alpha[3[[2-(3,4-dimethoxyphenyl) ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)hydrochloride) and the aldosterone receptor antagonist epoxymexrenone.

The present invention provides pharmaceutical formulations of decitabine or 5-aza-2′-deoxycytidine as well as methods of manufacturing the formulations. In particular, decitabine is formulated with a cyclodextrin compound to stabilize and / or enhance solubility of the drug. Kits and methods for using the pharmaceutical formulations are also provided, including methods of administering decitabine to treat conditions or diseases, such as cancer and hematological disorders.

A method predicting stroke evolution uses magnetic resonance diffusion and perfusion images obtained shortly after the onset of stroke symptoms to automatically estimate the eventual volume of dead cerebral tissue resulting from the stroke. The diffusion and perfusion images are processed to extract region(s) of interest presenting tissue at risk of infarction. A midplane algorithm is also used to calculate ratio and diffusion and perfusion measures for modelling infarct evolution. A parametric normal classifier algorithm is used to predict infarct growth using the calculated measures.

Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.

Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.

The present invention relates to methods and compositions which may be used to immunize infant mammals against a target antigen, wherein an immunogeniclly effective amount of a nuclic acid encoding a relevant epitope of a desired target antigen is administered to the infant. It is based, at least in part, on the discovery that such genetic immunization of infant mammals could give rise to effective cellular and humoral immune responses against target antigens.